U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H23F4N9O
Molecular Weight 553.5141
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ITACITINIB

SMILES

FC1=C(N=CC=C1C(=O)N2CCC(CC2)N3CC(CC#N)(C3)N4C=C(C=N4)C5=NC=NC6=C5C=CN6)C(F)(F)F

InChI

InChIKey=KTBSXLIQKWEBRB-UHFFFAOYSA-N
InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)

HIDE SMILES / InChI
Molecular Formula C26H23F4N9O
Molecular Weight 553.5141
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

INCB-039110 (also known as Itacitinib) is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity patented by Incyte Corporation for treatment of autoimmune disorders and cancer. Upon oral administration of NCB-039110, this agent selectively inhibits the phosphorylation and activity of JAK1, which may result in inhibition of JAK1-mediated signaling, induction of apoptosis, and reduction of cell proliferation in JAK1-expressing tumor cells. INCB-039110 in combination with nab-paclitaxel plus gemcitabine demonstrated an acceptable safety profile with clinical activity seen in patients with advanced solid tumors including pancreatic cancers. Based on the potential for additive or synergistic effects, NCB-039110 is currently being explored in combination with immunotherapeutic agents including the anti-programmed cell death protein 1 antibody and small molecule inhibitors.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 8.3 null [pIC50]
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
821 pmol/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32149388/
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ITACITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
410 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32149388/
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ITACITINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3360 pmol × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32149388/
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ITACITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
3362 nM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32149388/
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ITACITINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.18 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32149388/
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ITACITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
4.7 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32149388/
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ITACITINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
30.4%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32149388/
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ITACITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
PubMed

PubMed

TitleDatePubMed
Selective JAK inhibitors in development for rheumatoid arthritis.
2014-08
Patents

Patents

08765734
2
20110224190
1
WO2011112662
1

Sample Use Guides

In Vivo Use Guide
300 mg once daily
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:56:25 GMT 2025
Edited
by admin
on Mon Mar 31 19:56:25 GMT 2025
Record UNII
19J3781LPM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
itacitinib [INN]
Preferred Name English
ITACITINIB
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
INCB39110
Common Name English
INCB039110
Code English
(1-(1-(3-FLUORO-2-(TRIFLUOROMETHYL)PYRIDINE- 4-CARBONYL)PIPERIDIN-4-YL)-3-(4-(7H-PYRROLO(2,3-D)PYRIMIDIN- 4-YL)-1H-PYRAZOL-1-YL)AZETIDIN-3-YL)ACETONITRILE
Systematic Name English
Itacitinib [WHO-DD]
Common Name English
3-AZETIDINEACETONITRILE, 1-(1-((3-FLUORO-2-(TRIFLUOROMETHYL)-4-PYRIDINYL)CARBONYL)-4-PIPERIDINYL)-3-(4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-
Systematic Name English
INCB-39110
Code English
ITACITINIB [USAN]
Common Name English
INCB-039110
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 562716
Created by admin on Mon Mar 31 19:56:25 GMT 2025 , Edited by admin on Mon Mar 31 19:56:25 GMT 2025
NCI_THESAURUS C1967
Created by admin on Mon Mar 31 19:56:25 GMT 2025 , Edited by admin on Mon Mar 31 19:56:25 GMT 2025
NCI_THESAURUS C129825
Created by admin on Mon Mar 31 19:56:25 GMT 2025 , Edited by admin on Mon Mar 31 19:56:25 GMT 2025
EU-Orphan Drug EU/3/17/1964
Created by admin on Mon Mar 31 19:56:25 GMT 2025 , Edited by admin on Mon Mar 31 19:56:25 GMT 2025
Code System Code Type Description
USAN
CD-78
Created by admin on Mon Mar 31 19:56:25 GMT 2025 , Edited by admin on Mon Mar 31 19:56:25 GMT 2025
PRIMARY
DRUG BANK
DB12154
Created by admin on Mon Mar 31 19:56:25 GMT 2025 , Edited by admin on Mon Mar 31 19:56:25 GMT 2025
PRIMARY
SMS_ID
100000169938
Created by admin on Mon Mar 31 19:56:25 GMT 2025 , Edited by admin on Mon Mar 31 19:56:25 GMT 2025
PRIMARY
CAS
1334298-90-6
Created by admin on Mon Mar 31 19:56:25 GMT 2025 , Edited by admin on Mon Mar 31 19:56:25 GMT 2025
PRIMARY
PUBCHEM
53380437
Created by admin on Mon Mar 31 19:56:25 GMT 2025 , Edited by admin on Mon Mar 31 19:56:25 GMT 2025
PRIMARY
INN
10313
Created by admin on Mon Mar 31 19:56:25 GMT 2025 , Edited by admin on Mon Mar 31 19:56:25 GMT 2025
PRIMARY
ChEMBL
CHEMBL3544950
Created by admin on Mon Mar 31 19:56:25 GMT 2025 , Edited by admin on Mon Mar 31 19:56:25 GMT 2025
PRIMARY
EVMPD
SUB183665
Created by admin on Mon Mar 31 19:56:25 GMT 2025 , Edited by admin on Mon Mar 31 19:56:25 GMT 2025
PRIMARY
NCI_THESAURUS
C116855
Created by admin on Mon Mar 31 19:56:25 GMT 2025 , Edited by admin on Mon Mar 31 19:56:25 GMT 2025
PRIMARY
FDA UNII
19J3781LPM
Created by admin on Mon Mar 31 19:56:25 GMT 2025 , Edited by admin on Mon Mar 31 19:56:25 GMT 2025
PRIMARY
Related Record Type Details
TYROSINE-PROTEIN KINASE JAK3
OFF-TARGET->NON-INHIBITOR
IC50
NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2
TARGETF->WEAK INHIBITOR
IC50
TYROSINE-PROTEIN KINASE JAK2
WEAK INHIBITOR->TARGET
IC50
TYROSINE-PROTEIN KINASE JAK2
TARGET -> INHIBITOR
TYROSINE-PROTEIN KINASE JAK1
TARGET -> INHIBITOR
Structure of ITACITINIB ADIPATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of ITACITINIB
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966